Faeth Therapeutics Stock
Faeth Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Anand Parikh
- Employees
- 29
- Market cap
- $485 M
- IPO
- 04/02/2021
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
Faeth Therapeutics stock: price history
1D
-8.7%
1W
-27.8%
1M
-45.1%
6M
-38.3%
YTD
+76.2%
1Y
+6.9%
2Y
+104.8%
5Y
-87.7%
10Y
–
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~1% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Faeth Therapeutics
Analyst assessment of Faeth Therapeutics
PRICE TARGET LOW
US$50.00
CONSENSUS
US$58.50
MEDIAN
US$58.00
PRICE TARGET HIGH
US$70.00
0
STRONG BUY
5
BUY
0
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 11/08/2026
Faeth Therapeutics stock metrics
P/E
-0.13
P/B
0.61
EV/EBITDA
-2.35
RETURN ON EQUITY
-9.3%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
71.8%
FLOAT SHARES
18,511,047
AVG. DAILY VOLUME (30D)
409,662
Insider transactions (SEC)
STEPHENSON BRIAN C
STEPHENSON BRIAN C
STEPHENSON BRIAN C
STEPHENSON BRIAN C
STEPHENSON BRIAN C
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Faeth Therapeutics stock
What does Faeth Therapeutics do?
Faeth Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Anand Parikh, the company employs around 29 people.
The IPO was on 04/02/2021; the stock trades on NASDAQ under the ticker FTH.
What do analysts say about Faeth Therapeutics stock?
5 analysts rate the stock, the consensus is Buy (as of 11/08/2026).
The average price target is US$58.50, ranging from US$50.00 to US$70.00, with a median of US$58.00.
This is an external assessment, not a statement by Market Jury.
When does Faeth Therapeutics report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly 1% stronger than usual.
Does Faeth Therapeutics pay a dividend?
No, Faeth Therapeutics currently does not pay a dividend.
Which stocks are comparable to Faeth Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Faeth Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Faeth Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.